9724
2013
eng
article
1
--
--
--
Tumor Necrosis Factor Induces Tumor Promoting and Anti-Tumoral Effects on Pancreatic Cancer via TNFR1
Multiple activities are ascribed to the cytokine tumor necrosis factor (TNF) in health and disease. In particular, TNF was shown to affect carcinogenesis in multiple ways. This cytokine acts via the activation of two cell surface receptors, TNFR1, which is associated with inflammation, and TNFR2, which was shown to cause anti-inflammatory signaling. We assessed the effects of TNF and its two receptors on the progression of pancreatic cancer by in vivo bioluminescence imaging in a syngeneic orthotopic tumor mouse model with Panc02 cells. Mice deficient for TNFR1 were unable to spontaneously reject Panc02 tumors and furthermore displayed enhanced tumor progression. In contrast, a fraction of wild type (37.5%), TNF deficient (12.5%), and TNFR2 deficient mice (22.2%) were able to fully reject the tumor within two weeks. Pancreatic tumors in TNFR1 deficient mice displayed increased vascular density, enhanced infiltration of CD4+ T cells and CD4+ forkhead box P3 (FoxP3)+ regulatory T cells (Treg) but reduced numbers of CD8+ T cells. These alterations were further accompanied by transcriptional upregulation of IL4. Thus, TNF and TNFR1 are required in pancreatic ductal carcinoma to ensure optimal CD8+ T cell-mediated immunosurveillance and tumor rejection. Exogenous systemic administration of human TNF, however, which only interacts with murine TNFR1, accelerated tumor progression. This suggests that TNFR1 has basically the capability in the Panc02 model to trigger pro-and anti-tumoral effects but the spatiotemporal availability of TNF seems to determine finally the overall outcome.
PLoS ONE
10.1371/journal.pone.0075737
urn:nbn:de:bvb:20-opus-97246
Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany
PLoS ONE (2013) 8: 9, doi:10.1371/journal.pone.0075737
Martin Chopra
Isabell Lang
Steffen Salzmann
Christina Pachel
Sabrina Kraus
Carina A. Bäuerlein
Christian Brede
Ana-Laura Jordán Garrote
Katharina Mattenheimer
Miriam Ritz
Stefanie Schwinn
Carolin Graf
Viktoria Schäfer
Stefan Frantz
Hermann Einsele
Harald Wajant
Andreas Beilhack
eng
uncontrolled
Bioluminescence
eng
uncontrolled
cancer treatment
eng
uncontrolled
cell staining
eng
uncontrolled
cytokines
eng
uncontrolled
immune cells
eng
uncontrolled
metastasis
eng
uncontrolled
regulatory T cells
eng
uncontrolled
T cells
Medizin und Gesundheit
open_access
Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II)
Medizinische Klinik und Poliklinik I
Medizinische Klinik und Poliklinik II
Förderzeitraum 2013
Deutsches Zentrum für Herzinsuffizienz (DZHI)
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/9724/Chopra_journal.pone.0075737.pdf
15803
2017
eng
e0173933
3
12
article
1
2018-02-23
--
--
The impact of pulmonary metastasectomy in patients with previously resected colorectal cancer liver metastases
Background
40–50% of patients with colorectal cancer (CRC) will develop liver metastases (CRLM) during the course of the disease. One third of these patients will additionally develop pulmonary metastases.
Methods
137 consecutive patients with CRLM, were analyzed regarding survival data, clinical, histological data and treatment. Results were stratified according to the occurrence of pulmonary metastases and metastases resection.
Results
39% of all patients with liver resection due to CRLM developed additional lung metastases. 44% of these patients underwent subsequent pulmonary resection. Patients undergoing pulmonary metastasectomy showed a significantly better five-year survival compared to patients not qualified for curative resection (5-year survival 71.2% vs. 28.0%; p = 0.001). Interestingly, the 5-year survival of these patients was even superior to all patients with CRLM, who did not develop pulmonary metastases (77.5% vs. 63.5%; p = 0.015). Patients, whose pulmonary metastases were not resected, were more likely to redevelop liver metastases (50.0% vs 78.6%; p = 0.034). However, the rate of distant metastases did not differ between both groups (54.5 vs.53.6; p = 0.945).
Conclusion
The occurrence of colorectal lung metastases after curative liver resection does not impact patient survival if pulmonary metastasectomy is feasible. Those patients clearly benefit from repeated resections of the liver and the lung metastases.
PLoS ONE
10.1371/journal.pone.0173933
urn:nbn:de:bvb:20-opus-158036
PLoS ONE 12(3): e0173933 (2017). DOI: 10.1371/journal.pone.0173933
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Armin Wiegering
Johannes Riegel
Johanna Wagner
Volker Kunzmann
Johannes Baur
Thorsten Walles
Ulrich Dietz
Stefan Loeb
Christoph-Thomas Germer
Ulrich Steger
Ingo Klein
eng
uncontrolled
hepatic resection
eng
uncontrolled
surgical resection
eng
uncontrolled
lung resection
eng
uncontrolled
curative resection
eng
uncontrolled
metastasis
eng
uncontrolled
colorectal cancer
eng
uncontrolled
cancer treatment
eng
uncontrolled
surgical oncology
Chirurgie und verwandte medizinische Fachrichtungen
open_access
Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I)
Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie
Institut für Klinische Biochemie und Pathobiochemie
Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II)
Förderzeitraum 2017
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/15803/Wiegering_Plos_One.pdf
11279
2014
eng
article
1
2015-05-07
--
--
The HSP70 Modulator MAL3-101 Inhibits Merkel Cell Carcinoma
Merkel Cell Carcinoma (MCC) is a rare and highly aggressive neuroendocrine skin cancer for which no effective treatment is available. MCC represents a human cancer with the best experimental evidence for a causal role of a polyoma virus. Large T antigens (LTA) encoded by polyoma viruses are oncoproteins, which are thought to require support of cellular heat shock protein 70 (HSP70) to exert their transforming activity. Here we evaluated the capability of MAL3-101, a synthetic HSP70 inhibitor, to limit proliferation and survival of various MCC cell lines. Remarkably, MAL3-101 treatment resulted in considerable apoptosis in 5 out of 7 MCC cell lines. While this effect was not associated with the viral status of the MCC cells, quantitative mRNA expression analysis of the known HSP70 isoforms revealed a significant correlation between MAL3-101 sensitivity and HSC70 expression, the most prominent isoform in all cell lines. Moreover, MAL3-101 also exhibited in vivo antitumor activity in an MCC xenograft model suggesting that this substance or related compounds are potential therapeutics for the treatment of MCC in the future.
10.1371/journal.pone.0092041
urn:nbn:de:bvb:20-opus-112795
PLoS ONE 9(4): e92041. doi:10.1371/journal.pone.0092041
Christian Adam
Anne Baeurle
Jeffrey L. Brodsky
David Schrama
Peter Wipf
Jürgen Christian Becker
Roland Houben
eng
uncontrolled
apoptosis
eng
uncontrolled
cancer treatment
eng
uncontrolled
cell staining
eng
uncontrolled
cultured fibroplasts
eng
uncontrolled
heat shock response
eng
uncontrolled
membrans proteins
eng
uncontrolled
polymerase chain reaction
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
Förderzeitraum 2014
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/11279/078_Adam_PLoS.pdf
13005
2013
eng
e71105
9
8
article
1
2016-03-16
--
--
Optical Detection and Virotherapy of Live Metastatic Tumor Cells in Body Fluids with Vaccinia Strains
Metastatic tumor cells in body fluids are important targets for treatment, and critical surrogate markers for evaluating cancer prognosis and therapeutic response. Here we report, for the first time, that live metastatic tumor cells in blood samples from mice bearing human tumor xenografts and in blood and cerebrospinal fluid samples from patients with cancer were successfully detected using a tumor cell-specific recombinant vaccinia virus (VACV). In contrast to the FDA-approved CellSearch system, VACV detects circulating tumor cells (CTCs) in a cancer biomarker-independent manner, thus, free of any bias related to the use of antibodies, and can be potentially a universal system for detection of live CTCs of any tumor type, not limited to CTCs of epithelial origin. Furthermore, we demonstrate for the first time that VACV was effective in preventing and reducing circulating tumor cells in mice bearing human tumor xenografts. Importantly, a single intra-peritoneal delivery of VACV resulted in a dramatic decline in the number of tumor cells in the ascitic fluid from a patient with gastric cancer. Taken together, these results suggest VACV to be a useful tool for quantitative detection of live tumor cells in liquid biopsies as well as a potentially effective treatment for reducing or eliminating live tumor cells in body fluids of patients with metastatic disease.
PLoS ONE
10.1371/journal.pone.0071105
urn:nbn:de:bvb:20-opus-130059
PLoS ONE 8(9): e71105. doi:10.1371/journal.pone.0071105
Huiqiang Wang
Nanhai G. Chen
Boris R. Minev
Martina Zimmermann
Richard J. Aguilar
Qian Zhang
Julia B. Sturm
Falko Fend
Yong A. Yu
Joseph Cappello
Ulrich M. Lauer
Aladar A. Szalay
eng
uncontrolled
lymph nodes
eng
uncontrolled
cancer treatment
eng
uncontrolled
metastatic tumors
eng
uncontrolled
breast cancer
eng
uncontrolled
blood
eng
uncontrolled
prostate cancer
eng
uncontrolled
ascites
eng
uncontrolled
mouse models
Biochemie
open_access
Lehrstuhl für Biochemie
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/13005/092_Optical Detection and Virotherapy.pdf
9686
2013
eng
article
1
--
--
--
Is the Image Quality of I-124-PET Impaired by an Automatic Correction of Prompt Gammas?
Objectives
The aim of this study is to evaluate the quality of I-124 PET images with and without prompt gamma compensation (PGC) by comparing the recovery coefficients (RC), the signal to noise ratios (SNR) and the contrast to F-18 and Ga-68. Furthermore, the influence of the PGC on the quantification and image quality is evaluated.
Methods
For measuring the image quality the NEMA NU2-2001 PET/SPECT-Phantom was used containing 6 spheres with a diameter between 10 mm and 37 mm placed in water with different levels of background activity. Each sphere was filled with the same activity concentration measured by an independently cross-calibrated dose calibrator. The “hot” sources were acquired with a full 3D PET/CT (Biograph mCT®, Siemens Medical USA). Acquisition times were 2 min for F-18 and Ga-68, and 10 min for I-124. For reconstruction an OSEM algorithm was applied. For I-124 the images were reconstructed with and without PGC. For the calculation of the RCs the activity concentrations in each sphere were determined; in addition, the influence of the background correction was studied.
Results
The RCs of Ga-68 are the smallest (79%). I-124 reaches similar RCs (87% with PGC, 84% without PGC) as F-18 (84%). showing that the quantification of I-124 images is similar to F-18 and slightly better than Ga-68. With background activity the contrast of the I-124 PGC images is similar to Ga-68 and F-18 scans. There was lower background activity in the I-124 images without PGC, which probably originates from an overcorrection of the scatter contribution. Consequently, the contrast without PGC was much higher than with PGC. As a consequence PGC should be used for I-124.
Conclusions
For I-124 there is only a slight influence on the quantification depending on the use of the PGC. However, there are considerable differences with respect to I-124 image quality.
PLoS ONE
10.1371/journal.pone.0071729
urn:nbn:de:bvb:20-opus-96863
In: PLoS ONE (2013) 8: 8, doi:10.1371/journal.pone.0071729
Michael Lassmann
Veronika Preylowski
Susanne Schlögl
Frédéric Schoenahl
Gerhard Jörg
Samuel Samnick
Andreas K. Buck
eng
uncontrolled
cancer treatment
eng
uncontrolled
health care
eng
uncontrolled
isotopes
eng
uncontrolled
photons
eng
uncontrolled
positron emission tomography
eng
uncontrolled
signal to noise ratio
eng
uncontrolled
super ultraviolet
eng
uncontrolled
thyroid carcinomas
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Förderzeitraum 2013
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/9686/Lassmann_journal.pone.0071729.pdf
17967
2016
eng
8
11
article
1
2019-04-24
--
--
Human Organotypic Lung Tumor Models: Suitable For Preclinical \(^{18}\)F-FDG PET-Imaging
Development of predictable in vitro tumor models is a challenging task due to the enormous complexity of tumors in vivo. The closer the resemblance of these models to human tumor characteristics, the more suitable they are for drug-development and –testing. In the present study, we generated a complex 3D lung tumor test system based on acellular rat lungs. A decellularization protocol was established preserving the architecture, important ECM components and the basement membrane of the lung. Human lung tumor cells cultured on the scaffold formed cluster and exhibited an up-regulation of the carcinoma-associated marker mucin1 as well as a reduced proliferation rate compared to respective 2D culture. Additionally, employing functional imaging with 2-deoxy-2-[\(^{18}\)F]fluoro-D-glucose positron emission tomography (FDG-PET) these tumor cell cluster could be detected and tracked over time. This approach allowed monitoring of a targeted tyrosine kinase inhibitor treatment in the in vitro lung tumor model non-destructively. Surprisingly, FDG-PET assessment of single tumor cell cluster on the same scaffold exhibited differences in their response to therapy, indicating heterogeneity in the lung tumor model. In conclusion, our complex lung tumor test system features important characteristics of tumors and its microenvironment and allows monitoring of tumor growth and -metabolism in combination with functional imaging. In longitudinal studies, new therapeutic approaches and their long-term effects can be evaluated to adapt treatment regimes in future.
PLoS ONE
10.1371/journal.pone.0160282
urn:nbn:de:bvb:20-opus-179678
PLoS ONE 2016, 11(8):e0160282. DOI:10.1371/journal.pone.0160282
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
David Fecher
Elisabeth Hofmann
Andreas Buck
Ralph Bundschuh
Sarah Nietzer
Gudrun Dandekar
Thorsten Walles
Heike Walles
Katharina Lückerath
Maria Steinke
eng
uncontrolled
lung and intrathoracic tumors
eng
uncontrolled
trachea
eng
uncontrolled
adenocarcinoma of the lung
eng
uncontrolled
cancer treatment
eng
uncontrolled
secondary lung tumors
eng
uncontrolled
pulmonary imaging
eng
uncontrolled
extracellular matrix
eng
uncontrolled
collagens
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie
Klinik und Poliklinik für Nuklearmedizin
Lehrstuhl für Tissue Engineering und Regenerative Medizin
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/17967/Fecher_Plos_One.pdf
11938
2014
eng
e104337
8
9
article
1
2015-09-29
--
--
Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis.
In summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great potential for effective treatment of FMC in animal model.
PLoS ONE
10.1371/journal.pone.0104337
urn:nbn:de:bvb:20-opus-119387
PLoS ONE 9(8): e104337. doi:10.1371/journal.pone.0104337
Marion Adelfinger
Ivaylo Gentschev
Julio Grimm de Guibert
Stephanie Weibel
Johanna Langbein-Laugwitz
Barbara Härtl
Hugo Murua Escobar
Ingo Nolte
Nanhai G. Chen
Richard J. Aguilar
Yong A. Yu
Qian Zhang
Alexa Frentzen
Aladar A. Szalay
eng
uncontrolled
antibodies
eng
uncontrolled
cancer treatment
eng
uncontrolled
carcinomas
eng
uncontrolled
vaccinia virus
eng
uncontrolled
oncolytic viruses
eng
uncontrolled
viral replication
eng
uncontrolled
cell cultures
eng
uncontrolled
enzyme-linked immunoassays
Krankheiten
open_access
Institut für Molekulare Infektionsbiologie
Theodor-Boveri-Institut für Biowissenschaften
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/11938/033_Adelfinger_PLOS_ONE.pdf
17821
2016
eng
12
11
article
1
2019-03-11
--
--
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
Background
Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision.
Methods
In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and grading.
Results
There has been a progressive reduction in the use of CHT in luminal A patients during the last decade. Neither univariate nor multivariate analyses showed any statistically significant differences in relapse free survival (RFS) with the addition of CHT to adjuvant HT, independent of the nodal status, age, tumor size or grading. Even for patients with more than 3 affected lymph nodes, there was no significant difference (univariate: p = 0.865; HR 0.94; 95% CI: 0.46–1.93; multivariate: p = 0.812; HR 0.92; 95% CI: 0.45–1.88).
Conclusions
The addition of CHT to HT provides minimal or no clinical benefit at all to patients with luminal A breast cancer, independent of the RFS-risk. Consequently, risk estimation cannot be the initial step in the decisional process. These findings–that are in line with several publications–should encourage the critical evaluation of applying adjuvant CHT to patients with luminal A breast cancer.
PLoS ONE
10.1371/journal.pone.0168730
urn:nbn:de:bvb:20-opus-178217
PLoS ONE 2016, 11(12):e0168730. DOI:10.1371/journal.pone.0168730
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Joachim Diessner
Manfred Wischnewsky
Maria Blettner
Sebastian Häusler
Wolfgang Janni
Rolf Kreienberg
Roland Stein
Tanja Stüber
Lukas Schwentner
Catharina Bartmann
Achim Wöckel
eng
uncontrolled
breast cancer
eng
uncontrolled
hormones
eng
uncontrolled
endocrine therapy
eng
uncontrolled
cancer detection and diagnosis
eng
uncontrolled
cancer treatment
eng
uncontrolled
cancer chemotherapy
eng
uncontrolled
lymph nodes
eng
uncontrolled
hormona therapy
Medizin und Gesundheit
open_access
Frauenklinik und Poliklinik
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/17821/Diessner_Plos_One.pdf
11309
2014
eng
article
1
2015-05-11
--
--
CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma
Background
Adrenocortical tumors comprise frequent adenomas (ACA) and rare carcinomas (ACC). Human cytochrome P450 2W1 (CYP2W1) is highly expressed in some cancers holding the potential to activate certain drugs into tumor cytotoxins.
Objective
To investigate the CYP2W1 expression in adrenal samples and its relationship with clinical outcome in ACC.
Material and Methods
CYP2W1 expression was investigated by qRT-PCR in 13 normal adrenal glands, 32 ACA, 25 ACC, and 9 different non-adrenal normal tissue samples and by immunohistochemistry in 352 specimens (23 normal adrenal glands, 33 ACA, 239 ACC, 67 non-adrenal normal or neoplastic samples).
Results
CYP2W1 mRNA expression was absent/low in normal non-adrenal tissues, but high in normal and neoplastic adrenal glands (all P<0.01 vs non-adrenal normal tissues). Accordingly, CYP2W1 immunoreactivity was absent/low (H-score 0–1) in 72% of non-adrenal normal tissues, but high (H-score 2–3) in 44% of non-adrenal cancers, in 65% of normal adrenal glands, in 62% of ACAs and in 50% of ACCs (all P<0.001 vs non-adrenal normal tissues), being significantly increased in steroid-secreting compared to non-secreting tumors. In ACC patients treated with mitotane only, high CYP2W1 immunoreactivity adjusted for ENSAT stage was associated with longer overall survival and time to progression (P<0.05 and P<0.01, respectively), and with a better response to therapy both as palliative (response/stable disease in 42% vs 6%, P<0.01) or adjuvant option (absence of disease recurrence in 69% vs 45%, P<0.01).
Conclusion
CYP2W1 is highly expressed in both normal and neoplastic adrenal glands making it a promising tool for targeted therapy in ACC. Furthermore, CYP2W1 may represent a new predictive marker for the response to mitotane treatment.
10.1371/journal.pone.0105855
urn:nbn:de:bvb:20-opus-113096
PLoS ONE 9(8): e105855. doi:10.1371/journal.pone.0105855
Cristina L. Ronchi
Silviu Sbiera
Marco Volante
Sonja Steinhauer
Vanessa Scott-Wild
Barbara Altieri
Matthias Kroiss
Margarita Bala
Mauro Papotti
Timo Deutschbein
Massimo Terzolo
Martin Fassnacht
Bruno Allolio
eng
uncontrolled
CYP2W1
eng
uncontrolled
cancer treatment
eng
uncontrolled
adrenal glands
eng
uncontrolled
carcinomas
eng
uncontrolled
drug therapy
eng
uncontrolled
hormones
eng
uncontrolled
immune response
eng
uncontrolled
immunohistochemistry techniques
eng
uncontrolled
surgical oncology
Medizin und Gesundheit
open_access
Pathologisches Institut
Medizinische Klinik und Poliklinik I
Förderzeitraum 2014
Comprehensive Cancer Center Mainfranken
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/11309/123_Ronchi_PLoS.pdf
11967
2014
eng
e98533
6
9
article
1
2015-10-02
--
--
Characterization of Metastasis Formation and Virotherapy in the Human C33A Cervical Cancer Model
More than 90% of cancer mortalities are due to cancer that has metastasized. Therefore, it is crucial to intensify research on metastasis formation and therapy. Here, we describe for the first time the metastasizing ability of the human cervical cancer cell line C33A in athymic nude mice after subcutaneous implantation of tumor cells. In this model, we demonstrated a steady progression of lumbar and renal lymph node metastases during tumor development. Besides predominantly occurring lymphatic metastases, we visualized the formation of hematogenous metastases utilizing red fluorescent protein (RFP) expressing C33A-RFP cells. RFP positive cancer cells were found migrating in blood vessels and forming micrometastases in lungs of tumor-bearing mice. Next, we set out to analyze the influence of oncolytic virotherapy in the C33A-RFP model and demonstrated an efficient virus-mediated reduction of tumor size and metastatic burden. These results suggest the C33A-RFP cervical cancer model as a new platform to analyze cancer metastases as well as to test novel treatment options to combat metastases.
PLoS ONE
10.1371/journal.pone.0098533
1932-6203
24887184
urn:nbn:de:bvb:20-opus-119674
PLoS ONE 9(6): e98533. doi:10.1371/journal.pone.0098533
Ulrike Donat
Juliane Rother
Simon Schäfer
Michael Hess
Barbara Härtl
Christina Kober
Johanna Langbein-Laugwitz
Jochen Stritzker
Nanhai G. Chen
Richard J. Aguilar
Stephanie Weibel
Alandar A. Szalay
eng
uncontrolled
metastasis
eng
uncontrolled
renal cancer
eng
uncontrolled
oncolytic viruses
eng
uncontrolled
lymph nodes
eng
uncontrolled
kidneys
eng
uncontrolled
lung and intrathoracic tumors
eng
uncontrolled
secondary lung tumors
eng
uncontrolled
cancer treatment
Krankheiten
open_access
Rudolf-Virchow-Zentrum
Lehrstuhl für Biochemie
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/11967/047_Donat_PLOS_ONE.pdf